The UIC islet transplant research team successfully completed a Phase 1 clinical trial in which all 10 participants achieved insulin independence after 1-3 islet transplants. Although the duration of islet graft survival cannot be predicted, participants report that freedom from glycemic lability and life-threatening hypoglycemic episodes is a life-changing vacation from diabetes. These patients and numerous others who contact us provide incentive for us to advance the science of islet transplantation.
The Islet Transplant Research Program at University of Illinois at Chicago (UIC) is recruiting participants for three clinical trials to test the efficacy of islet transplantation for patients with type 1 diabetes. These trials are sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) and theNational Institute of Diabetes & Digestive & Kidney Diseases (NIDDK).
The studies, designed as prospective, multi-center, randomized Phase 3 trials, are being conducted by the Clinical Islet Transplantation Consortium (CIT). CIT is comprised of a small number of experienced islet transplant centers in the US and Canada. Over 200 patients are expected to enroll.